{
    "clinical_study": {
        "@rank": "157982", 
        "acronym": "HANDLE", 
        "arm_group": [
            {
                "arm_group_label": "intravitreal aflibercept injection", 
                "arm_group_type": "Experimental", 
                "description": "Group A -Monthly intravitreal aflibercept injection for 3 months (Baseline, Months 1 and 2), then mandatory  every 2 months intravitreal aflibercept injection (Months 4,6, 8 and 10)for 12 months. Monthly visits with evaluations for as needed intravitreal aflibercept injection.\n."
            }, 
            {
                "arm_group_label": "intravitreal aflibercept", 
                "arm_group_type": "Experimental", 
                "description": "Group B- One intravitreal aflibercept injection at Baseline, then monthly visits with evaluations for as needed dosing of intravitreal aflibercept injection for 12 months."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to monitor safety outcomes for patients being treated with\n      intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed\n      Ocular Histoplasmosis Syndrome."
        }, 
        "brief_title": "Treatment for Presumed Ocular Histoplasmosis", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ocular Histoplasmosis", 
        "condition_browse": {
            "mesh_term": [
                "Histoplasmosis", 
                "Choroidal Neovascularization"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Active choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis\n             demonstrated by active leakage on fluorescein angiography with spectal domain OCT\n             evidence of subretinal or intraretinal fluid or PED.\n\n          -  Active CNV may also be defined as demonstrating active subretinal hemorrhage.\n\n          -  ETDRS Best corrected visual acuity 20/20-20/320.\n\n          -  willing and able to comply with all study clinic visits and study related procedures.\n\n          -  Willing to use and practice more than one form of contraceptives during the 13 month\n             study for male and female.\n\n          -  Provide signed informed consent\n\n          -  Able to understand and complete study related questionnaires\n\n        Exclusion Criteria:\n\n          -  Under 18 years of age\n\n          -  CNV due to other causes than Presumed Ocular Histoplasmosis\n\n          -  Previous treatment in the study eye within 6 months prior to Day 1\n\n          -  More than 5 Intravitreal injections of anti-VEGF therapy within previous 12 months\n\n          -  Any clinical evidence of any other ocular condition other than Ocular histoplasmosis\n\n          -  History of allergy to fluorescein\n\n          -  Pregnant( or planning on becoming pregnant within the next 13 months) or breast\n             feeding women\n\n          -  Sexually Active Men or Women who are NOT willing to practice more than one form of\n             contraceptives during the next 13 months.\n\n          -  Anticipated or previous (within previous 3 months) systemic anti-VEGF therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790893", 
            "org_study_id": "IND 117497"
        }, 
        "intervention": {
            "arm_group_label": [
                "intravitreal aflibercept injection", 
                "intravitreal aflibercept"
            ], 
            "intervention_name": "aflibercept", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Histoplasmosis", 
        "lastchanged_date": "October 16, 2013", 
        "link": {
            "url": "http://www.retinaky.com"
        }, 
        "location": [
            {
                "contact": {
                    "email": "jgardner@southeastretina.com", 
                    "last_name": "Jared Gardner", 
                    "phone": "706-650-0061"
                }, 
                "contact_backup": {
                    "email": "ccaulder@southeastretina.com", 
                    "last_name": "Courtney Caulder", 
                    "phone": "706-650-0061"
                }, 
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30909"
                    }, 
                    "name": "Southeast Retina"
                }, 
                "investigator": [
                    {
                        "last_name": "Dennis Marcus, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Harinderjit Singh, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dholcomb@retinaky.com", 
                    "last_name": "Diana Holcomb", 
                    "phone": "859-264-2905"
                }, 
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40509"
                    }, 
                    "name": "Retina Associates of Kentucky"
                }, 
                "investigator": [
                    {
                        "last_name": "John W. Kitchens, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "William J Wood, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Tom Stone, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Rick Isernhagen, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Andrew Moshfeghi, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Megan Kingdon", 
                    "phone": "513-569-3669"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }, 
                    "name": "Cincinnati Eye Institute"
                }, 
                "investigator": [
                    {
                        "last_name": "Daniel Miller, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Michael Petersen, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Robert Sisk, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Robert Foster, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Christopher Riemann, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Brian Toussaint, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Intravitreal Aflibercept Injection for the Treatment of cHoroidAl Neovascularization seconDary to Presumed ocuLar Histoplasmosis syndromE.(the HANDLE Study)", 
        "other_outcome": {
            "description": "Mean change from baseline in central subfield thickness over time up to 12 months assessed on OCT", 
            "measure": "OCT changes", 
            "safety_issue": "Yes", 
            "time_frame": "baseline to 12 months"
        }, 
        "overall_contact": {
            "email": "dholcomb@retinaky.com", 
            "last_name": "Diana Holcomb, COA", 
            "phone": "859-264-2905"
        }, 
        "overall_official": {
            "affiliation": "Retina Associates of Kentucky", 
            "last_name": "John W Kitchens, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of the study is the incidence and severity of ocular and systemic adverse events through Month 12", 
            "measure": "ocular and systemic adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "through Month 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790893"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Retina Associates of Kentucky", 
            "investigator_full_name": "John Kitchens, MD", 
            "investigator_title": "Sponsor-Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Mean change in BCVA from Baseline\nProportion of subjects gaining >5,10 and 15 letters\nProportion of subjects losing >5, 10 and 15 letters", 
            "measure": "Visual acuity", 
            "safety_issue": "Yes", 
            "time_frame": "Months 3, 6, 9 and 12"
        }, 
        "source": "Retina Associates of Kentucky", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "John Kitchens, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}